August 13, 2025 — Kalaris Therapeutics Inc. (Nasdaq: KLRS) reported its second quarter financial results and provided a business update, according to a press release.
The clinical-stage biopharmaceutical company is continuing enrollment of nAMD patients in a Phase 1 trial of TH103. TH103 is a novel anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina. Initial clinical data is expected in Q4 2025.
Kalaris had cash and cash equivalents of $88.4 million as of June 30, 2025, which is expected to fund operations into Q4 2026.
The company is currently enrolling a Phase 1 single ascending dose trial to assess the safety, pharmacokinetics, and preliminary treatment effect of TH103 in neovascular Age-related Macular Degeneration (nAMD) patients.
Kalaris recently expanded its leadership team with the hire of Kristine Curtiss, Senior Vice President of Clinical.
For the quarter ended June 30, 2025, net loss was $11.4 million or $0.61 per share, compared with a net loss of $5.7 million or $4.26 per share for the quarter ended June 30, 2024.
Contact: Corey Davis, Ph.D., LifeSci Advisors, LLC, +1 212 915 2577, cdavis@lifesciadvisors.com, ir@kalaristx.com
Source: Kalaris Therapeutics, Inc.
